jetcityimage/iStock Editorial via Getty Images
Eli Lilly (NYSE:LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk’s (NVO) Wegovy (semaglutide) in a Phase 3b head-to-head trial.
The detailed results from the 72-week SURMOUNT-5 trial, published in The New England Journal